FDA accepts for priority review New Drug Application for oral paclitaxel and encequidar in metastatic breast cancer

Application is based on pivotal phase III study comparing safety and efficacy of this oral monotherapy with IV paclitaxel monotherapy, which achieved primary endpoint showing statistically significant improvement in overall response rate, along with a lower rate neuropathy vs IV.


Biospace Inc.